A multi-institutional analysis of repeat tumor or plasma biopsies from patients with RET fusion-positive NSCLC treated with selpercatinib and pralsetinib identified the emergence of MET amplification (15%) and KRAS amplification in one case each.12 The gene discussed is RET; the disease is non-small cell lung carcinoma.